









Markets
/
Stocks
/
nasdaq-prtc
/

PureTech Health PLC

PRTC

16.500USD

-1.000-5.71%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

3.96BMarket Cap

--P/E TTM



PureTech Health PLC

16.500

-1.000-5.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PureTech Health PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PureTech Health PLC's Score

Industry at a Glance

Industry Ranking

256 / 501

Overall Ranking

460 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

46.000

Target Price

+162.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

PureTech Health PLC Highlights

StrengthsRisks

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.83M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 101.38, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 355.84K shares, decreasing 14.97% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92. Its latest quarterly revenue reached 4.54M, representing a year-over-year increase of 2422.22%, while its net profit experienced a year-over-year increase of 334.15%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

PureTech Health PLC's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is 101.38, which is 150.66% below the recent high of 254.13 and 100.00% above the recent low of 0.00.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 256/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for PureTech Health PLC is 46.00, with a high of 46.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

10.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

46.000

Target Price

+162.86%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

PureTech Health PLC

PRTC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.68, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 24.94 and the support level at 5.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.67

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.204

Neutral

RSI(14)

47.072

Neutral

STOCH(KDJ)(9,3,3)

25.569

Sell

ATR(14)

0.736

High Vlolatility

CCI(14)

-145.003

Sell

Williams %R

100.000

Oversold

TRIX(12,20)

0.100

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

17.068

Sell

MA10

17.282

Sell

MA20

17.567

Sell

MA50

16.850

Sell

MA100

17.518

Sell

MA200

17.711

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Pentwater Capital Management LP

50.00K

+48.99%

Portolan Capital Management, L.L.C.

27.80K

+133.87%

Millennium Management LLC

23.86K

-46.88%

Diadema Partners LP

7.32K

Persistent Asset Partners Limited

1.69K

Geode Capital Management, L.L.C.

770.00

Dimensional Fund Advisors, L.P.

316.00

UBS Financial Services, Inc.

20.00

Fidelity Management & Research Company LLC

1.28K

Atlantic Union Bankshares Corporation

115.00

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.